This Author published in this journals
All Journal Pharmacy Reports
Manami Toriyama
Laboratory of Advanced Cosmetic Science, Graduate School of Pharmaceutical Science, Osaka University, Japan 565-0871

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

In silico screening of cucurbitacin variants identifies 11-deoxycucurbitacin I as a candidate ligand for the NACHT domain of NLRP3 Sarmoko; Ahmad Zammi Autadan Hakim; Nisa Yulianti Suprahman; Refsya Azanti Putri; Muhammad Yogi Saputra; Tantri Liris Nareswari; Manami Toriyama
Pharmacy Reports Vol. 6 No. 2 (2026): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.125

Abstract

Chronic inflammation contributes to a wide range of diseases, driving the need for novel anti-inflammatory agents with minimal side effects. The NACHT domain of NLRP3 mediates ATP-dependent inflammasome assembly and represents a validated target for anti-inflammatory therapy. This study aimed to predict and compare the binding interactions of twenty-two cucurbitacin variants against the NACHT domain using molecular docking, following geometry optimization with Density Functional Theory (B3LYP/6-31G(d)). Docking validation reproduced the native ligand pose with an RMSD of 0.87 angstrom. Among all variants tested, 11-deoxycucurbitacin I showed the most favorable predicted binding energy (-7.38 kcal/mol), sharing several interacting residues with the native ligand RM5, including Ala227, Ala228, Pro352, Ile411, Phe575, and Met661, although its predicted affinity remained weaker than that of RM5 (-10.35 kcal/mol). These shared contacts suggest that 11-deoxycucurbitacin I may engage a similar region of the NACHT inhibitor-binding pocket as RM5. In conclusion, 11-deoxycucurbitacin I is identified as the most favorable predicted binder among the cucurbitacin variants tested toward the NACHT domain, representing a candidate warranting further experimental validation.